Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 09 Mar 2023
Swissmedic issues unlimited authorisation for booster dose of Moderna's bivalent COVID-19 Original/Omicron BA.4-5 vaccine
8 March 2023 - Spikevax bivalent Original/Omicron BA.4-5 mRNA vaccine authorised for people aged 18 and over. ...
Posted by Michael Wonder on 09 Mar 2023
AMA urges immediate action to save patients on PBS medicines
9 March 2023 - The AMA has urged all members of the Federal Parliament to support the AMA’s campaign to bring ...
Posted by Michael Wonder on 09 Mar 2023
Patent system key to lower drug prices, experts say
9 March 2023 - Following the Biden administration’s progress towards lowering prescription drug prices with Medicare price negotiations, some industry ...
Posted by Michael Wonder on 09 Mar 2023
New drugs are coming to market at sky-high prices
9 March 2023 - Trend follows rising pressure on companies to rein in repeat or annual price hikes for older drugs/ ...
Posted by Michael Wonder on 09 Mar 2023
Mallinckrodt announces reimbursement approval in Japan for the Celllex extracorporeal photopheresis system for the treatment of chronic graft versus host disease
9 March 2023 - Cellex ECP is now available for reimbursement in Japan for patients who are steroid-resistant or intolerant ...
Posted by Michael Wonder on 09 Mar 2023
CADTH recommends reimbursement for BioCryst’s Orladeyo (berotralstat) for the routine prevention of attacks in hereditary angioedema patients in Canada
8 March 2023 - BioCryst Pharmaceuticals today announced that the CADTH Canadian Drug Expert Committee has issued a positive recommendation ...
Posted by Michael Wonder on 09 Mar 2023
Use warranties, not outcomes-based agreements, to make payers whole when a gene therapy fails
9 March 2023 - A decade ago, I had pegged gene and cell therapies as the next frontier. As an ...
Posted by Michael Wonder on 09 Mar 2023
Updates from the Health Technology Assessment Policy and Methods Review Reference Committee (March 2023)
9 March 2023 - The Health Technology Assessment Policy and Methods Review Reference Committee met on 13 February 2023. ...
Posted by Michael Wonder on 08 Mar 2023
Jazz Pharmaceuticals secures eight additional provincial reimbursements for Vyxeos for treatment of adults with newly diagnosed therapy-related acute myeloid leukaemia or acute myeloid leukaemia with myelodysplasia-related changes
8 March 2023 - Jazz Pharmaceuticals announced today that Vyxeos (daunorubicin and cytarabine liposome for injection) is now included on eight ...
Posted by Michael Wonder on 08 Mar 2023
Biden calls for tax on the wealthy to extend Medicare funding
8 March 2023 - President Joe Biden this week called for higher taxes on wealthy Americans to extend Medicare funding as ...
Posted by Michael Wonder on 08 Mar 2023
Preterm birth drug withdrawn after 12 years
7 March 2023 - The FDA seemed poised to rescind approval of Makena, after studies over time indicated the treatment did ...
Posted by Michael Wonder on 08 Mar 2023
Amphastar Pharmaceuticals receives FDA approval for naloxone hydrochloride nasal spray 4 mg
8 March 2023 - Amphastar Pharmaceuticals announced that the US FDA has granted approval of its new drug application for ...
Posted by Michael Wonder on 08 Mar 2023
US FDA accepts supplemental new drug application for Jardiance for children 10 years and older with type 2 diabetes
8 March 2023 - The application is based on phase III results from the DINAMO trial showing Jardiance (empagliflozin) tablets significantly ...
Posted by Michael Wonder on 08 Mar 2023
NICE recommended weight loss drug to be made available in specialist NHS services
8 March 2023 - Thousands of people will soon be able to be prescribed a drug to help them lose weight ...
Posted by Michael Wonder on 08 Mar 2023
FDA accepts Mesoblast’s resubmission of the biologic license application for remestemcel-L in children with steroid-refractory acute graft versus host disease as a complete response
7 March 2023 - If approved, remestemcel-L will be the first allogeneic “off the shelf” cellular medicine in the US and ...